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Reinvigorating Immune
Response to Advanced
Melanoma
Melanoma represents a small fraction of skin cancerrelated malignancies, yet accounts for the majority
of its mortalities—and the incidence of cutaneous
melanoma is rising. While treatments using smalltargeted inhibitors and immune checkpoint antibodies
have increased long-term survival in advancedstage cutaneous melanoma, many patients still
do not realize any benefit from the treatments.
Another group of patients initially have beneficial
results but ultimately find their disease progressing,
in part due to cancer cells’ acquired resistance to
immune response. And still other patients have
difficulty with the treatment’s high toxicity.
Emad Alnemri, PhD, Thomas Eakins Professor of
Biochemistry and Molecular Biology, and Andrew
Aplin, PhD, Kalbach-Newton Professor of Cancer
Research, have been leading a series of studies of the
molecular processes that determine whether or not
current inhibitor and immune checkpoint treatments
will work well in melanoma patients, and for how
long. Now, based on the results of those studies,
they are working to develop new, more-effective
treatment approaches that address three goals:
triggering a robust anti-tumor immune response that
has significant clinical effect, preventing onset of
acquired resistance and minimizing patient toxicities.
Over the past two years, their research team
announced a series of important findings that help
to address the question of why initially successful
immune system-focused therapies for patients with
stage III and stage IV melanoma often fail within
13 months, due primarily to tumor cells acquiring
resistance to the drugs. “Previously, the field has lacked
detailed knowledge of exactly how targeted inhibitors
and immune checkpoint agents work together to
fight melanoma tumors—how they prompt both
tumor-cell death and alterations in the tumor-immune
environment,” Dr. Alnemri explains. “However, our
studies have described a molecular mechanism of
targeted inhibitor regulation of an immune-stimulatory
form of cell death. In identifying the mechanism,
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we have been able to describe a proof-of-principle
therapy concept for melanoma tumors that are
resistant to inhibitor-based treatments.”
A key to the new therapeutic approach is the
researchers’ discoveries on the molecular
mechanisms by which the gasdermin E gene and its
expressed protein function. The gasdermin E protein
normally participates in the cell-death program—
which, among other purposes, is intended to kill
malignant cells. And in many cancers, gasdermin E
expression is much lower than it is in healthy cells.
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The researchers found that gasdermin E participates
in the cell-death process by spurring creation
of holes in a cell’s outer membrane and its
mitochondrial membrane. “Next,” Dr. Aplin says,
“looking at the role that gasdermin E plays in
malignancies, we found that cancer-cell lines
without gasdermin E multiplied about twice as
fast as normal cells. Moreover, in mice models of
melanoma, cells lacking gasdermin E grew larger
tumors—where, in contrast, cancer cells retaining
some gasdermin E expression had slower growth.”
Thus, Drs. Alnemri and Aplin concluded, gasdermin
E could provide several clinical opportunities. “Not
only could it be used as a marker to distinguish
aggressive tumors from less-aggressive ones,”
Dr. Alnemri explains, “it could be employed to
help design effective treatment strategies.”
Perhaps more exciting is the potential for using
gasdermin E as a new therapeutic target.
To that end, they are now developing approaches
for promoting gasdermin E expression as a method
for reinvigorating the immune system in melanoma
tumors that have proven resistant to current
treatments. “In simplified terms, we are working
to boost and restore the immune system’s natural
ability to kill melanoma cells,” says Dr. Aplin. “And we
hope that it may also prove effective in other cancers
where gasdermin E expression is suppressed.” 
Tumour immunofluorescence
IHC image. Aggressive metastatic
Melanoma Tumor cells in green with
blue nuclei invading into the skin.
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